<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; EVVV</title>
	<atom:link href="http://www.stockbloghub.com/tag/evvv/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Announces They Will Aquire Micrus Endovascular</title>
		<link>http://www.stockbloghub.com/2010/07/25/jnj-johnson-johnson-announces-they-will-aquire-micrus-endovascular/43222</link>
		<comments>http://www.stockbloghub.com/2010/07/25/jnj-johnson-johnson-announces-they-will-aquire-micrus-endovascular/43222#comments</comments>
		<pubDate>Sun, 25 Jul 2010 17:56:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43222</guid>
		<description><![CDATA[Johnson &#38; Johnson (JNJ) recently announced plans to acquire medical devices maker Micrus Endovascular Corp. (MEND), based in San Jose, California, for $480 million in cash or $23.40 per share for each of Micrus’ 20.5 million shares outstanding. The offer price represents a 5.5% premium over the closing price of Micrus’ shares on July 9. The boards of directors of both the companies have approved the deal, which now awaits shareholder and regulatory approval. The deal, which is scheduled to close in the second half of 2010, is expected to be breakeven to slightly dilutive to Johnson &#38; Johnson’s 2010 earnings per share. Johnson &#38; Johnson expects 2010 earnings in the range of $4.80 to $4.90 per share on total revenues of $63.5 billion to $64.0 billion. At the time ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/25/jnj-johnson-johnson-announces-they-will-aquire-micrus-endovascular/43222/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Files for FDA Pre-Market Approval</title>
		<link>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947</link>
		<comments>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947#comments</comments>
		<pubDate>Fri, 21 May 2010 16:25:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37947</guid>
		<description><![CDATA[ev3, Inc. (EVVV) has recently filed the final module of its Pre-market Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for its Pipeline Embolization Device. The company expects the FDA to schedule an advisory panel review of the proposal in late 2010 and the product approval in 2011. The Pipeline Embolization Device is used for treating large, giant and wide-neck aneurysms. The PUFS (Pipeline for Uncoilable or Failed AneurysmS) was a single-arm study of large and giant, wide-neck or fusiform aneurysms that are typically not coilable. The study enrolled and treated 108 patients at 10 centers in the U.S. and Europe. Results were positive with safety and effectiveness endpoints being achieved. The Pipeline Embolization Device is an alternative to present endovascular or surgical treatment options available in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/21/evvv-ev3-files-for-fda-pre-market-approval/37947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Enters Agreement With MEDRAD</title>
		<link>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299</link>
		<comments>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:29:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33299</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently entered a new agreement with MEDRAD, Inc. Per the agreement, ev3’s SilverHawk and TurboHawk Plaque Excision Systems will be used in combination with MEDRAD’s Cotavance peripheral drug-eluting balloon angioplasty catheter for use in the DEFINITIVE AR (Anti-Restenosis) European pilot study. The DEFINITIVE AR study evaluates the use of SilverHawk or TurboHawk Plaque Excision Systems along with the Cotavance drug-eluting balloon catheter compared to the use of the Cotavance balloon catheter alone in patients with peripheral arterial disease (PAD). The DEFINITIVE AR study will evaluate up to 125 patients in Europe. ev3 expects to commence the study from the second half of 2010. A global multicenter pivotal trial will start soon after the pilot study gets completed. ev3’s SilverHawk and TurboHawk Plaque Excision Systems are catheter-based technologies. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/evvv-ev3-enters-agreement-with-medrad/33299/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Analyst Downgrades to Neutral</title>
		<link>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685</link>
		<comments>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:47:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29685</guid>
		<description><![CDATA[We have recently downgraded ev3 Inc. (EVVV) to Neutral with a target price of $16 based on a P/E of roughly 35.6x our fiscal 2010 EPS estimate of 45 cents. We downgraded the stock based on a downtrend in earnings estimates in the past 30 days. During the 30-day period, six out of ten analysts downgraded their earnings estimates while only three have upgraded theirs for the first quarter of fiscal 2010. For the second quarter, five out of ten analysts have downgraded their earnings estimates while only three have upgraded theirs. For fiscal 2010, seven out of ten analysts downgraded their earnings estimates while only two have upgraded theirs. For fiscal 2011, four have downgraded while only one analyst has upgraded his earnings estimate out of a panel of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/evvv-ev3-analyst-downgrades-to-neutral/29685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Reports Earnings In-Line With Consensus</title>
		<link>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898</link>
		<comments>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:21:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28898</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently reported fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were 12 cents, in line with the Zacks Consensus Estimate and higher than the year-ago loss of 2 cents. For fiscal 2009, earnings per share were 40 cents, higher than the loss of 45 cents in the year-ago quarter. Quarterly results Excluding the Merck research collaboration revenues, net sales increased 20% year over year to $126.8 million in the fourth quarter. Excluding a favorable foreign currency translation (FX), net sales increased 16% year over year. Peripheral vascular sales increased 8% year over year to $73.7 million. Growth was led by higher demand for the company’s plaque excision; thrombectomy and embolic protection; and procedural support products. This was partly offset by lower ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/evvv-ev3-reports-earnings-in-line-with-consensus/28898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CSII) Cardiovascular Systems Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084</link>
		<comments>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084#comments</comments>
		<pubDate>Sat, 16 Jan 2010 00:26:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Inc]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25084</guid>
		<description><![CDATA[Cardiovascular Systems, Inc. (CSII) recently received the U.S. Food and Drug Administration’s (FDA) conditional Investigational Device Exemption (IDE) approval. The approval is meant to evaluate the safety and effectiveness of the company’s Diamondback 360 degree System used to treat calcified coronary lesions. Cardiovascular Systems is now authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites. The Diamondback 360 degree Orbital Atherectomy System is a minimally invasive catheter system used in the treatment of peripheral arterial disease (PAD). It has been estimated that the peripheral arterial disease affects eight to twelve million people. It is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg), thus reducing blood flow. Diamondback 360 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Completes TrailBlazer Support Catheter Recall</title>
		<link>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448</link>
		<comments>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448#comments</comments>
		<pubDate>Fri, 08 Jan 2010 20:33:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24448</guid>
		<description><![CDATA[ev3, Inc. (EVVV) recently completed a voluntary Class I recall of its TrailBlazer Support Catheter. The catheter was recalled as a result of the device cracking near its marker band. ev3 received these complaints from physicians during the initial limited market release of the device in the U.S. The company initiated the recall of these devices from November 2009. ev3 recalled roughly 350 individual catheters and at present has the possession of all the affected units. The company has already sent a final closure report regarding the voluntary recall of the affected catheters to the U.S. Food &#38; Drug Administration (FDA). The company also launched a redesigned TrailBlazer Support Catheter globally in December 2009. We think that the recall of these devices will have a minimal impact on the company’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/08/evvv-ev3-completes-trailblazer-support-catheter-recall/24448/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EVVV) ev3 Beats Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032</link>
		<comments>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:30:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19032</guid>
		<description><![CDATA[ev3, Inc. (EVVV), the Zacks Bull of the Day for last Friday (October 23rd), reported third quarter 2009 earnings per share of 17 cents, easily beating the Zacks Consensus Estimate of 2 cents and the year-ago earnings of 4 cents. Sales Net sales in the reported quarter increased 5.4% year over year to $112.8 million. Excluding the research collaboration revenues, net sales increased 12.8% year over year. The company generated research collaboration revenues despite the termination of its agreement with Merck &#38; Co. Inc. (MRK), which ended July 22, 2008. On a geographic basis and excluding the research collaboration revenues, U.S. contributed approximately 61% to total sales and increased 8% year over year. International revenues increased 21% year over year. Growth was seen in all business segments. Peripheral vascular sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/evvv-ev3-beats-consensus-earnings-estimates/19032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CSII) Cardiovascular Systems&#8217; Portfolio Gets Expanded in Marketing Agreement</title>
		<link>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804</link>
		<comments>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804#comments</comments>
		<pubDate>Fri, 28 Aug 2009 22:59:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Incorporated]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[Ev3 Incorporated]]></category>
		<category><![CDATA[EVVV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13804</guid>
		<description><![CDATA[Yesterday, Cardiovascular Systems Inc. (CSII) announced that it has agreed to market Japan-based Asahi Intecc Co. Ltd’s peripheral guide wire line in the United States. The peripheral guide wires address long, complex lesions above or below the knee, and complement the plaque removal capabilities of Cardiovascular’s main product, the Diamondback 360. The company intends to offer two Asahi 0.18 wire platforms; the Astato 30 and Treasure 12. This agreement not only expands Cardiovascular’s product portfolio but also consolidates its top position in the peripheral arterial disease (PAD) market. This agreement is in tune with the company’s mission to provide in excess of 5,000 physicians and 2,000 hospitals treating PAD with comprehensive endovascular tools. The Diamondback 360 Orbital Atherectomy System is a minimally invasive catheter system used for PAD treatment. PAD ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/csii-cardiovascular-systems-portfolio-gets-expanded-in-marketing-agreement/13804/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CSII) Cardiovascular Systems Better Than Expected Results</title>
		<link>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916</link>
		<comments>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Incorporated]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[Ev3 Incorporated]]></category>
		<category><![CDATA[EVVV]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12916</guid>
		<description><![CDATA[Cardiovascular Systems, Inc. (CSII) reported better-than-expected results for the fourth quarter of fiscal 2009. For the quarter, its loss per share was 40 cents, better than the Zacks Consensus Estimate of 58 cents and the year-ago loss per share of $2.34. Quarterly results Sales Net sales in the quarter increased roughly 59% year over year to $15.7 million. Growth was primarily due to increased adoption of company product the Diamondback 3600.  The number of hospitals using the Diamondback 3600 was 556, compared to 183 at the end of the year-ago quarter. Higher sales of disposable devices also contributed to the total growth in net sales. The number of disposable devices sold in the quarter was 4,700 units, compared to 3,000 units in the year-ago quarter. Margins Gross margin increased 1,020 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/cardiovascular-systems-better-than-expected-results/12916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

